Overview
Inger Nijhof practices practicing medicine in Nieuwegein, Netherlands.
Ms. Nijhof is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), and COVID-19.
She is actively involved in clinical research, co-authoring 58 peer reviewed articles.
Gender
Locations
Nieuwegein, UT, Netherlands
Almere Stad, FL, Netherlands
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Inger S. Nijhof
Is Inger S. Nijhof a top-rated expert for Multiple Myeloma?
MediFind is an objective health platform that identifies experts based on real-world data. Inger S. Nijhof is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Inger S. Nijhof participate in research or clinical trials?
Yes. Inger S. Nijhof has published 58 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Inger S. Nijhof's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chronic Graft Versus Host Disease (cGvHD)Ms. Nijhof isDistinguished. Learn about Chronic Graft Versus Host Disease (cGvHD).
- Multiple MyelomaMs. Nijhof isDistinguished. Learn about Multiple Myeloma.
- Experienced
- AnemiaMs. Nijhof isExperienced. Learn about Anemia.
- B-Cell LymphomaMs. Nijhof isExperienced. Learn about B-Cell Lymphoma.
- Chronic B-Cell Leukemia (CBCL)Ms. Nijhof isExperienced. Learn about Chronic B-Cell Leukemia (CBCL).
- Chronic Lymphocytic Leukemia (CLL)Ms. Nijhof isExperienced. Learn about Chronic Lymphocytic Leukemia (CLL).
- Congenital Hemolytic AnemiaMs. Nijhof isExperienced. Learn about Congenital Hemolytic Anemia.
- COVID-19Ms. Nijhof isExperienced. Learn about COVID-19.
- Graft Versus Host Disease (GvHD)Ms. Nijhof isExperienced. Learn about Graft Versus Host Disease (GvHD).
- HemoglobinopathyMs. Nijhof isExperienced. Learn about Hemoglobinopathy.
- Hemolytic AnemiaMs. Nijhof isExperienced. Learn about Hemolytic Anemia.
- Mantle Cell Lymphoma (MCL)Ms. Nijhof isExperienced. Learn about Mantle Cell Lymphoma (MCL).
- Non-Hodgkin LymphomaMs. Nijhof isExperienced. Learn about Non-Hodgkin Lymphoma.
- Relapsed Refractory Multiple Myeloma (RRMM)
- Severe Acute Respiratory Syndrome (SARS)
- Sickle Cell DiseaseMs. Nijhof isExperienced. Learn about Sickle Cell Disease.
- XanthomaMs. Nijhof isExperienced. Learn about Xanthoma.